A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerUrothelial CarcinomaSalivary Gland CancerPancreatic CancerHER-2 Protein Overexpression
Interventions
DRUG

Zanidatamab

Administered by intravenous (IV) infusion

Trial Locations (21)

13620

RECRUITING

Seoul National University Bundang Hospital, Seoul

19044

RECRUITING

Alliance Cancer Specialists, Horsham

24014

RECRUITING

Blue Ridge Cancer Care, Roanoke

32827

RECRUITING

Florida Cancer Specialists - Lake Nona, Orlando

33401

RECRUITING

Florida Cancer Specialists - East, West Palm Beach

33705

RECRUITING

Florida Cancer Specialists - North, St. Petersburg

33901

RECRUITING

Florida Cancer Specialists - South, Fort Myers

37203

RECRUITING

SCRI Oncology Partners, Nashville

37909

RECRUITING

Tennessee Cancer Specialists, Knoxville

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

60415

RECRUITING

Affiliated Oncologists, Chicago Ridge

75246

RECRUITING

Texas Oncology - DFW, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

78217

RECRUITING

Texas Oncology - San Antonio, San Antonio

79124

RECRUITING

Texas Oncology - West Texas, Amarillo

80120

RECRUITING

Rocky Mountain Cancer Center, Littleton

86301

RECRUITING

Arizona Oncology Associates, PC - NAHOA, Prescott

06351

RECRUITING

Samsung Medical Center, Gangnam-gu

03080

RECRUITING

Seoul National University Hospital, Jongno-gu

03722

RECRUITING

Severance Hospital, Seodaemun-gu

05505

RECRUITING

Asan Medical Center, Seoul

All Listed Sponsors
collaborator

Jazz Pharmaceuticals Ireland Limited

INDUSTRY

lead

Jazz Pharmaceuticals

INDUSTRY